EGFR and non-small cell lung carcinoma: Two classes of molecularly targeted therapies, EGFR‐tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase inhibitors, were recently introduced into clinical practice to treat patients with NSCLC.5